NGX 267

Drug Profile

NGX 267

Alternative Names: AF 267B; NGX-267

Latest Information Update: 11 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Horizon Pharma; Life Science Research Israel
  • Developer Raptor Pharmaceutical Corp
  • Class Antidementias; Nootropics; Piperidines; Small molecules; Spiro compounds; Thiazolidines
  • Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Cognition disorders; Xerostomia

Most Recent Events

  • 03 Nov 2009 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
  • 03 Nov 2009 Discontinued - Phase-I for Cognition disorders in Belgium (PO)
  • 03 Nov 2009 Discontinued - Phase-II for Xerostomia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top